Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

MD Anderson Cancer Center, University of Texas, Houston, TX, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Houston, TX
Treatments:ChemotherapyHospital:MD Anderson Cancer Center, University of Texas
Drugs:Journal:Link
Date:Mar 2010

Description:

Patients:
This phase 2 study involved 39 women with platinum refractory or resistant ovarian cancer. The median age was 54.5 years, with a range of 34.8-75.4.

Treatment:
Patients received a combination of two chemotherapeutic agents, canfosfamide (also known as TELCYTA or TLK286) and pegylated liposomal doxorubicin.

Toxicity:
The highest toxicity level observed in this study was Grade 4, mostly consisting of neutropenia. Other adverse events observed at a level less that 4 included nausea, fatigue, hair loss, and stomatitis (inflammation of the mouth).

Results:
The median overall survival reported in this study was 17.8 months. The reported median progression-free survival was 6 months.

Support:
Several of the authors are employed by Telik, Inc, the makers of canfosfamide.

Correspondence: Dr. Gail L. Brown



Back